From the Guidelines
Tobramycin ophthalmic solution at a concentration of 14 mg/ml is recommended for the treatment of eye discharge during radiation therapy for basal cell carcinoma of the eyelid skin, prepared by withdrawing 2 ml from an injectable vial of intravenous tobramycin (40 mg/ml) and adding it to a 5-ml bottle of tobramycin ophthalmic solution 1. To prepare the solution, follow these steps:
- Withdraw 2 ml from an injectable vial of intravenous tobramycin (40 mg/ml)
- Add the withdrawn 2 ml to a 5-ml bottle of tobramycin ophthalmic solution to give a 14 mg/ml solution
- Refrigerate and shake well before instillation The treatment should be applied as follows:
- Apply 1-2 drops of the prepared tobramycin ophthalmic solution to the affected eye(s) every 4 hours
- Alternatively, a small ribbon (approximately 1/2 inch) of tobramycin ophthalmic ointment can be applied to the inside of the lower eyelid 2-3 times daily
- Continue treatment for the duration prescribed by your healthcare provider, usually until the discharge resolves or for 7-10 days It is essential to follow proper hygiene and application techniques to prevent contamination and ensure the effectiveness of the treatment, as supported by the most recent and highest quality study 1.
From the FDA Drug Label
DOSAGE AND ADMINISTRATION: In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation. The recommended dose and direction for tobramycin for a patient with eye discharge is:
- Mild to moderate disease: 1 or 2 drops into the affected eye(s) every 4 hours.
- Severe infections: 2 drops into the eye(s) hourly until improvement. 2
From the Research
Tobramycin Dose and Directions
There are no research papers to assist in answering this question regarding the recommended dose and direction for tobramycin for a patient with eye discharge during radiation therapy for basal cell carcinoma of the eyelid skin. The provided studies 3, 4, 5, 6, 7 focus on the treatment of basal cell carcinoma using radiation therapy, but do not mention the use of tobramycin or its dosage for eye discharge during this treatment.
Key Points
- The studies provided discuss radiation therapy as a treatment for basal cell carcinoma of the eyelid skin.
- They report on the efficacy and safety of radiation therapy in treating this condition, with varying doses and fractions used.
- None of the studies mention the use of tobramycin or provide guidance on its dosage for eye discharge during radiation therapy.
- Therefore, there is no relevant information available from these studies to answer the question about tobramycin dose and directions in this context.